This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Cesarone, M.R. Articles by Belcaro, G. Search for Related Content PubMed PubMed Citation Articles by Cesarone, M.R. Articles by Belcaro, G. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB ACETYLSALICYLIC ACID Medline Plus Health Information Blood Thinners Social Bookmarking                         What's this?

Effects of Triflusal on Arteriosclerosis Progression Assessed with High-Resolution Arterial Ultrasound

Cardiovascular Institute, G. D'annunzio University, Chieti; ACV (Angiology & Vascular - Surgery), Pierangeli Clinic, Pescara, Italy

G. Laurora, MD

Cardiovascular Institute, G. D'annunzio University, Chieti; ACV (Angiology & Vascular - Surgery), Pierangeli Clinic, Pescara, Italy

M.T. DeSanctis, MD

Cardiovascular Institute, G. D'annunzio University, Chieti; ACV (Angiology & Vascular - Surgery), Pierangeli Clinic, Pescara, Italy

L. Incandela, MD

Cardiovascular Institute, G. D'annunzio University, Chieti; ACV (Angiology & Vascular - Surgery), Pierangeli Clinic, Pescara, Italy

L. Fugazza, MD

Medicine Division, Predabissi Hospital, Melegnano, Milan, I Italy.

R. Girardello, MD

Research and Development Department, Poli Industria Chimica S.p.A., Milan, Italy.

A. Poli, MD

Statistics and Biometrics Unit, Poli Industria Chimica S.p.A., Milan, Italy.

L. Peracino, PhD

Statistics and Biometrics Unit, Poli Industria Chimica S.p.A., Milan, Italy.

L. Ambrosoli, MD

Research and Development Department, Poli Industria Chimica S.p.A., Milan, Italy.

G. Belcaro, MD

Cardiovascular Institute, G. D'annunzio University, Chieti; ACV (Angiology & Vascular - Surgery), Pierangeli Clinic, Pescara, Italy

In order to evaluate the effect of triflusal (2-acetyloxy-4-trifluoromethyl benzoic acid), an orally active antiplatelet agent, on arteriosclerosis progression, a pilot, parallel, double- dummy, double-blind clinical trial vs acetylsalicylic acid (ASA) was carried out in patients with subclinical atherosclerotic lesions. The trial consisted of a 2-week run-in placebo phase, followed by a 12-month oral treatment with triflusal (600 mg/day) or ASA (300 mg/day). The primary variable was identified in the ultrasonic biopsy (UB) score; the secondary variables were the UB class changes of each arterial site, the rate of progres sion (ROP), the intima-media thickness (IMT), and the symptoms of arteriosclerosis. Data were evaluated by use of analysis of variance and Chi-square test. Forty-three patients (31 men, 12 women, mean age 62.8 ±8.4 SD) were randomized to triflusal (15 men, 6 women, mean age 64.3 ±6.7) or to ASA (16 men, 6 women, mean age 61.3 ± 9.6) . The analysis of variance on the UB score showed no difference between treat (Abstract continued) ments: the patients' UB scores remained unchanged with no progression, thus indicating that no patient worsened during treatment. When all arterial sites under evaluation are considered, 86% of the sites in the triflusal group and 85% in the ASA group remained unchanged. No relevant change was recorded in vital signs and routine laboratory tests. Gastric disturbances were reported by two and three patients treated with triflusal and ASA, respectively. In conclusion, triflusal appears as effective as ASA in slowing arterio sclerosis progression.

Angiology, Vol. 50, No. 6, 455-463 (1999)
DOI: 10.1177/000331979905000603


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?